As of 2024-12-13, the Relative Valuation of Enorama Pharma AB (ERMA.ST) is (17.08) SEK. This relative valuation is based on P/E multiples. With the latest stock price at 3.10 SEK, the upside of Enorama Pharma AB based on Relative Valuation is -651.1%.
The range of the Relative Valuation is (14.53) - (17.06) SEK.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 14.2x - 30.5x | 23.0x |
| Forward P/E multiples | 18.8x - 22.1x | 21.2x |
| Fair Price | (14.53) - (17.06) | (17.08) |
| Upside | -568.8% - -650.5% | -651.1% |
| Date | P/E |
| 2024-12-09 | -4.21 |
| 2024-12-06 | -4.21 |
| 2024-12-05 | -4.48 |
| 2024-12-04 | -4.40 |
| 2024-12-03 | -4.09 |
| 2024-12-02 | -4.25 |
| 2024-11-29 | -4.48 |
| 2024-11-28 | -4.60 |
| 2024-11-27 | -4.68 |
| 2024-11-26 | -4.87 |
| 2024-11-25 | -5.04 |
| 2024-11-22 | -4.88 |
| 2024-11-21 | -5.00 |
| 2024-11-20 | -5.30 |
| 2024-11-19 | -5.48 |
| 2024-11-18 | -5.06 |
| 2024-11-15 | -5.08 |
| 2024-11-14 | -5.12 |
| 2024-11-13 | -5.17 |
| 2024-11-12 | -4.93 |
| 2024-11-11 | -4.91 |
| 2024-11-08 | -4.69 |
| 2024-11-07 | -4.97 |
| 2024-11-06 | -4.97 |
| 2024-11-05 | -5.10 |
| 2024-11-04 | -4.66 |
| 2024-11-01 | -4.77 |
| 2024-10-31 | -5.02 |
| 2024-10-30 | -5.23 |
| 2024-10-29 | -4.90 |
| 2024-10-28 | -4.97 |
| 2024-10-25 | -5.10 |
| 2024-10-24 | -5.13 |
| 2024-10-23 | -4.99 |
| 2024-10-22 | -5.08 |
| 2024-10-21 | -5.18 |
| 2024-10-18 | -5.31 |
| 2024-10-17 | -5.18 |
| 2024-10-16 | -5.97 |
| 2024-10-15 | -5.37 |
| 2024-10-14 | -5.27 |
| 2024-10-11 | -5.44 |
| 2024-10-10 | -5.44 |
| 2024-10-09 | -5.45 |
| 2024-10-08 | -5.94 |
| 2024-10-07 | -6.01 |
| 2024-10-04 | -5.62 |
| 2024-10-03 | -5.61 |
| 2024-10-02 | -5.36 |
| 2024-10-01 | -5.61 |